About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

April 17, 2015

click here to read more

Post navigation

Phosphagenics Appoints Three New Directors

Appendix 3X Notices – Three New Directors

Related Posts

Quarterly Activities Report and 4C – to 30 June 2022

July 29, 2022July 29, 2022

Phosphagenics Signs Japanese License Option Agreement for TPM Oxycodone Patch

May 17, 2016

Phosphagenics Signs Japanese License Option Agreement and R&D Alliance

April 29, 2016

Recent Posts

First Patient Dosed in Phase III Insomnia Trial
May 16, 2024
MEDIA | Channel 9 News
March 28, 2024
Avecho’s Phase III Clinical Trial for Insomnia Commences
March 26, 2024

Categories

Analyst Coverage
Company Announcement
Company Report
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.